Lung Cancer | Specialty

PD-L1 Predictive of Response to MK-3475 in Melanoma and NSCLC

April 7th 2014

PD-L1 levels adequately predict response and clinical outcomes for PD-1 inhibitor MK-3475 in patients with non-small cell lung cancer (NSCLC) and melanoma

Institute Develops Fresh Bench-to-Bedside Model Through Community Ties

April 3rd 2014

In more than 40 years as a National Cancer Institute (NCI)-designated cancer center-and the first center in the network devoted purely to basic research-The Wistar Institute has built a reputation for furthering the sort of scientific research that will improve clinical cancer medicine.

Dr. Halmos on Checkpoint Inhibitors in Lung Cancer

April 2nd 2014

Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, discusses the anti-PD-L1 antibody MK-3475 and the challenge of integrating immunotherapies into the field of lung cancer.

MAGE-A3 Vaccine Falters in Large Phase III NSCLC Study

April 2nd 2014

The large phase III MAGRIT study investigating the MAGE-A3-specific vaccine GSK1572932A for patients with non-small cell lung cancer (NSCLC) will be completely halted following an interim analysis that demonstrated a lack of benefit.

Next-Generation EGFR Inhibitor Shows Promise in Resistant NSCLC

March 31st 2014

The next-generation EGFR inhibitor CO-1686 has demonstrated promising activity in T790M-positive patients with non-small cell lung cancer.

Ceritinib Demonstrates Impressive Response Rates in ALK-Positive NSCLC

March 27th 2014

Ceritinib (LDK378) demonstrated an ORR of 58% and a median PFS of 7 months as a treatment for patients with ALK-positive non-small cell lung cancer.

Dr. Halmos on the Implications of the IPASS Study

March 26th 2014

Balazs Halmos, MD, section chief of Thoracic Oncology at NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the implication of the IPASS study.

MAGE-A3 Antigen-Specific Vaccine Fails to Extend DFS in NSCLC

March 20th 2014

The MAGE-A3-specific immunotherapeutic GSK1572932A failed to significantly extend disease-free survival (DFS) in patients with resected nonmetastatic non-small cell lung cancer (NSCLC) who tested negative for a specific gene expression signature

Dr. Lynch on Molecular Profiling in Lung Cancer

March 18th 2014

Thomas J. Lynch, MD, Richard Sackler and Jonathan Sackler Professor of Medicine (Medical Oncology), director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital at Yale-New Haven, Giant of Lung Cancer Care, discusses advances in molecular profiling in lung cancer.

Peregrine's Lead Agent Receives FDA Fast Track Designation for NSCLC

March 4th 2014

Bavituximab, Peregrine Pharmaceuticals' lead clinical immunotherapeutic candidate, received Fast Track designation from the FDA to kick off 2014.

Onartuzumab Falters in Late-Stage NSCLC Trial

March 3rd 2014

A phase III study exploring the MET inhibitor onartuzumab as a treatment for patients with NSCLC is being stopped, following an interim analysis that suggested a lack of clinically meaningful efficacy.

Immune Checkpoint Blockade in Cancer: Inhibiting CTLA-4 and PD-1/PD-L1 With Monoclonal Antibodies

February 21st 2014

Inhibitory receptors such as anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1) expressed on tumor-specific T cells lead to compromised activation and suppressed effector functions such as proliferation, cytokine secretion, and tumor cell lysis.

Ramucirumab Combination Improves OS and PFS in NSCLC

February 19th 2014

The second-line administration of ramucirumab in combination with docetaxel has shown a statistically significant improvement in overall survival and progression-free survival compared with placebo plus docetaxel in patients with non-small cell lung cancer

Dr. Herbst on Immunotherapy Agents in Lung Cancer

February 13th 2014

Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses the using immunotherapy agents to treat patients with lung cancer.

Hopes Revived for Targeting the "Undruggable" RAS Family

February 11th 2014

The members of the RAS oncogene family are central cogs in many different cell-signaling pathways, coordinate a variety of important cellular processes, and are highly mutated in a number of different cancers, including several with extremely poor prognosis.

Dr. Shaw on LDK378 and Alectinib for ALK+ NSCLC

February 10th 2014

Alice T. Shaw, MD, PhD, discusses the two most advanced next-generation ALK-inhibitors for the treatment of non-small cell lung cancer (NSCLC): LDK378 and alectinib (AF802).

Final Thoughts on Improving Outcomes in NSCLC

February 7th 2014

Skeletal-Related Event Management in Lung Cancer

February 7th 2014

Next-Generation Sequencing in Lung Cancer

February 7th 2014

Determining When to Administer Maintenance Therapy in NSCLC

February 7th 2014